San Diego, CA 92101, US
Biotechnology
www.neurocrine.com
Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The companys research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.
Larry is a Special Limited Partner and currently serves as Chairman of Lux Ventures’ Advisory Board of industry experts advising the Investment Team. Larry was a co-founder and executive chairman of Nanosys, Inc. Prior to Nanosys, he was a managing general partner of CW Group, a life sciences venture capital fund. Larry was also a general partner of Avalon Ventures, a seed stage venture capital firm.
Larry has been the founder and initial chief executive officer of Metra Biosystems, Inc., Neurocrine Biosciences, Inc. (NASDAQ: NBIX – neuroimmunology), Pharmacopeia, Inc. (NASDAQ: PCOP – combinatorial chemistry), Argonaut Technologies, Inc (NASDAQ: AGNT – combinatorial chemistry), and Caliper Technologies Corp (NASDAQ: CALP – lab-on-a-chip). Mr. Bock was also a co-founder of ARIAD Pharmaceuticals, Inc (NASDAQ: ARIA – intra cellular signal transduction), Athena Neurosciences (NASDAQ: ATHN, acquired by Elan Pharmaceuticals for $700M – molecular neurobiology) Inc.
Gary A. Lyons has over 30 years of experience in the biopharmaceutical industry.
Most recently he was the President and Chief Executive Officer of Neurocrine Biosciences, Inc., a public biotechnology company focused on neurological and endocrine diseases and disorders.
Prior to joining Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development, Vice President of Sales, and Director of Sales and Marketing.
In addition to serving on the board of directors of KaloBios, he also currently serves on the boards of directors of Neurocrine Biosciences, Rigel Pharmaceuticals, Inc., Vical Incorporated and Poniard Pharmaceuticals.
Mr. Lyons holds a B.S. degree in marine biology from the University of New Hampshire and an M.B.A. from Northwestern Universitys J.L. Kellogg Graduate School of Management.
Mr. Mahmood joined Obalon in October 2012. Over the past 20 years he has held a number of marketing and sales roles with both small biotech and large pharmaceutical companies. Most recently he was Senior Director of Marketing at Amylin Pharmaceuticals.
President & CEO at Neurocrine Biosciences
David Schnell is a co-founder and Managing Director of Prospect Venture Partners, a venture capital firm dedicated to investing in and supporting emerging biomedical companies. Since 1997, Prospect has raised and manages more than a $1B.
David serves or has served on the Board of Directors of Gloucester Pharmaceuticals (NASDAQ:CELG acquired), Healtheon (NASDAQ: WBMD), Kythera Biopharmaceuticals, Lux Biosciences, Microcide (NASDAQ:MCDE), Neurocrine (NASDAQ:NBIX), NGM Biopharmaceuticals, Nora Therapeutics, Rinat Neuroscience (NYSE:PFE acquired), Senomyx (NASDAQ:SNMX), Trubion (NYSE: EBS acquired) as well as Amira Pharmaceuticals (NYSE: BMS acquired) and several others.
Mr. Pops has served as a member of Accelerons board of directors since 2004.
Since 2009, Mr. Pops has served as Chief Executive Officer and Chairman of the board of Alkermes.From 2007 to 2009 he served as the Chairman of the board of Alkermes, and from 1991 through 2007 he served as the Chief Executive Officer of Alkermes.Mr. Pops also serves on the board of directors of Neurocrine Biosciences, Inc., Epizyme Inc., the Biotechnology Industry Organization and Pharmaceutical Researcher and Manufacturers of America.
He has previously served on the board of directors of Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Inc. from 2001 to 2009.Mr. Pops also served on the board of directors of Reliant Pharmaceuticals, a privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris Venture Partners.He was a member of the Harvard Medical School Board of Fellows from 2002 through June 2012.
Mr.
Dr. Vale was Head of The Clayton Foundation Laboratories for Peptide Biology at the Salk Institute.
He was also an Adjunct Professor of Medicine at the University of California, San Diego. Dr. Vale was recognized for his work on the molecular, pharmacological and biomedical characterization of more than a dozen neuroendocrine peptides, growth factors and their receptors.
He was a co-founder and member of the Board of Directors of Neurocrine Biosciences, a public company, founded in part based upon his groups identification and study of peptides and receptors mediating the endocrine, metabolic and behavioral responses to stress.
Dr. Vales group has also characterized activin A, a member of the TGF-beta/BMP family of growth factors as well as the activin receptor type II, the first signaling receptor for this family.
Mr. Lacasse joined GeneChem at its inception in 1997. Prior to that, he was Vice-President of Healthcare and Biotechnology at Sofinov, a wholly owned venture capital subsidiary of Caisse de dpt et placement du Qubec. In total, he spent ten years with the Caisse where he was responsible for numerous investments in small and medium sized businesses in cutting-edge industries such as biotechnology, software and telecommunications. Mr. Lacasse has been involved in a number of very successful investments in companies such as BioChem Pharma inc., Axcan Pharma inc., and Neurocrine Biosciences inc. Mr.
Lacasse is or has been a member of the board of directors of several companies including BioChem Pharma inc., Axcan Pharma inc. and Metrowerks inc. He has held positions with the Bank of Montreal and with the Centre de dveloppement technologique of cole Polytechnique de Montral.
Mr. Lacasse obtained a Bachelors degree in finance from the cole des Hautes tudes Commerciales (HEC) and a M.
Zachary Hornby brings a dozen years of life sciences business experience to Ignyta.
Prior to joining Ignyta, Mr. Hornby was senior director of business development at Fate Therapeutics where he was responsible for pharmaceutical partnerships and non-dilutive funding.
Mr. Hornby has also served in various business and commercial roles at Halozyme Therapeutics (NASDAQ: HALO), Neurocrine Biosciences (NASDAQ: NBIX) and TKT (now Shire Human Genetic Therapies), and was a life sciences consultant at L.E.K. Consulting.
Mr. Hornby holds B.S. and M.S. degrees in biology from Stanford University and an M.B.A. from Harvard Business School.
In addition to his role as chairman and CEO at Fate, Bill also currently serves as Chairman of the Board at Receptos, Illumina and Neurocrine Biosciences.
Bill is a partner at Venrock, which he joined in 2006 from Biogen Idec, where he was most recently executive chairman. Bill joined Idec Pharmaceuticals at its founding in 1986 and grew it to a multi-billion-dollar market valuation company, while serving as Chairman and CEO. He was at Biogen Idec from the merger of the two companies in 2003, through the end of 2005.
Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and also served in a scientific capacity at the company. Adding to his corporate background, Bill held various faculty positions at MIT, won the award for Excellence in the Teaching of Chemistry at Harvard and is an Alfred P. Sloan Fellow.
Kimberly Hebert is the Director, Clinical Operations at Adynxx Inc.
Kimberly Hebert joined Adynxx in October 2011 as Director, Clinical Operations.
Her career has spanned 14 years in the biotech industry, starting as a Clinical Operations Assistant, and has held positions of increasing responsibility at,
Alliance Pharmaceutical, Corp.,
Neurocrine Biosciences, Inc.,
NovaCardia, Inc.,
Merck & Co., Inc. (after NovaCardia was acquired by Merck in 2007).
Most recently, she led clinical operations for an international Phase 3 study sponsored by Corthera, Inc., and continued to lead operations for the project after Corthera’s acquisition by Novartis in early 2010.
Kim studied in the Clinical Trials Design and Management Extension program at the University of California, San Diego in 2001-2002 and previously studied at the University of Colorado, Boulder.
Prior Year Revenue | Current Year Revenue | Next Year Revenue |
---|---|---|
Sign up as Investor | Sign up as Investor | Sign up as Investor |
Company Age | Employees | Sub-Industry |
---|---|---|
25 years, 4 months | 13 | Other Biotechnology |
Company Type | Stock Exchange | Stock Symbol |
---|---|---|
Privately-Held | – | – |